US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

CervoMed

8.30

+0.09001.10%

Post-market: 8.18-0.1200-1.45%18:03 EST

Volume:93.01K

Turnover:753.49K

Market Cap:76.80M

PE:-2.89

High:8.39

Open:8.11

Low:7.51

Close:8.21

52wk High:16.94

52wk Low:1.80

Shares:9.25M

Float Shares:4.93M

Volume Ratio:0.93

T/O Rate:1.88%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.8732

EPS(LYR):-2.0179

ROE:-71.42%

ROA:-42.78%

PB:2.95

PE(LYR):-4.11

Loading ...

Overview Company News Filings

Director and 10% Owner Sylvie Gregoire Acquires Common Shares of Cervomed Inc

CervoMed CEO John J. Alam Reports Acquisition of Common Shares

CervoMed Executives Make Bold Moves with Significant Stock Purchases!

CervoMed CFO William Robert Elder Reports Acquisition of Common Shares

CervoMed’s Strategic Advancements and Clinical Trial Developments Drive Buy Rating

CervoMed Is Maintained at Buy by D. Boral Capital

Canaccord Genuity Sticks to Their Buy Rating for CervoMed (CRVO)

CervoMed price target lowered to $19 from $20 at Roth Capital

CervoMed Q3 EPS $(0.84) Misses $(0.49) Estimate, Sales $322.569K Miss $1.300M Estimate

CervoMed Q3 net loss widens

CervoMed reports Q3 2025 grant revenue of $0.3 million

Press Release: CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

CervoMed Inc expected to post a loss of 77 cents a share - Earnings Preview

CervoMed Shares Rise After HC Wainwright Upgrade

MT Newswires Live

Roth MKM Keeps Their Buy Rating on CervoMed (CRVO)

HC Wainwright Upgrades CervoMed to Buy From Neutral, Adjusts Price Target to $25 From $11

MT Newswires Live

CervoMed upgraded to Buy from Neutral at H.C. Wainwright

CervoMed Inc : H.c. Wainwright Raises Target Price to $25 From $11

THOMSON REUTERS

CervoMed’s Strategic Phase 3 Trial Progress for Neflamapimod Boosts Buy Rating

CervoMed Is Maintained at Buy by D. Boral Capital

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CRVO/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CRVO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","market":"US","secType":"STK","nameCN":"CervoMed","latestPrice":8.3,"timestamp":1763499600000,"preClose":8.21,"halted":0,"volume":93008,"hourTrading":{"tag":"盘后","latestPrice":8.18,"preClose":8.3,"latestTime":"18:03 EST","volume":166,"amount":1361.525,"timestamp":1763507005376},"delay":0,"floatShares":4934300,"shares":9252719,"eps":-2.873156,"marketStatus":"Closed","change":0.09,"latestTime":"11-18 16:00:00 EST","open":8.11,"high":8.39,"low":7.51,"amount":753488.779664,"amplitude":0.107186,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.873156,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1763542800000},"marketStatusCode":5,"adr":0,"exchange":"NASDAQ","adjPreClose":8.21,"preHourTrading":{"tag":"盘前","latestPrice":8.5,"preClose":8.21,"latestTime":"08:00 EST","volume":317,"amount":2652.7618780000003,"timestamp":1763470807307},"postHourTrading":{"tag":"盘后","latestPrice":8.18,"preClose":8.3,"latestTime":"18:03 EST","volume":166,"amount":1361.525,"timestamp":1763507005376},"volumeRatio":0.934949},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CRVO\",,,,,undefined,":{"symbol":"CRVO","floatShares":4934300,"roa":"-42.78%","roe":"-71.42%","lyrEps":-2.017884,"volumeRatio":0.934949,"shares":9252719,"dividePrice":0,"high":8.39,"amplitude":0.107186,"preClose":8.21,"low":7.51,"week52Low":1.8,"pbRate":"2.95","psRate":"12.47","week52High":16.94,"institutionHeld":0,"latestPrice":8.3,"eps":-2.873156,"divideRate":0,"volume":93008,"delay":0,"ttmEps":-2.873156,"open":8.11,"prevYearClose":2.34,"prevWeekClose":7.68,"prevMonthClose":7.05,"prevQuarterClose":8.09,"fiveDayClose":6.97,"twentyDayClose":7.22,"sixtyDayClose":9.43},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CRVO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-07","symbol":"CRVO","fiscalQuarterEnding":"2025/09","expectedEps":-0.68,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1762491600000,"reportTimeType":"post","actualEps":-0.84},{"market":"US","date":"2025-08-08","symbol":"CRVO","fiscalQuarterEnding":"2025/06","expectedEps":-0.57,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754625600000,"reportTimeType":"pre","actualEps":-0.7},{"market":"US","date":"2025-05-12","symbol":"CRVO","fiscalQuarterEnding":"2025/03","expectedEps":-0.6,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.56},{"market":"US","date":"2025-03-17","symbol":"CRVO","fiscalQuarterEnding":"2024/12","expectedEps":-0.67,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"pre","actualEps":-0.8},{"market":"US","date":"2024-11-12","symbol":"CRVO","fiscalQuarterEnding":"2024/09","expectedEps":-0.41,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-0.55}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CRVO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CRVO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":7,"updateTime":1762837200000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CRVO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CRVO","date":"2025-11-17","current":-2.801414,"percent":0.871377,"low":-119.682483,"twenty":-38.637925,"median":-7.191777,"eighty":-3.324397,"high":-1.31262,"avg":-21.914308,"sd":24.95525,"marketCap":71060881},"quantilePoints":[{"date":"2023-09-01","current":-5.788607,"twenty":-5.849231,"median":-5.813052,"eighty":-5.769051,"marketCap":33591560},{"date":"2023-09-08","current":-5.135433,"twenty":-5.817941,"median":-5.700604,"eighty":-4.975855,"marketCap":29801161},{"date":"2023-09-15","current":-4.791246,"twenty":-5.769051,"median":-5.182368,"eighty":-4.935961,"marketCap":27803825},{"date":"2023-09-22","current":-4.51746,"twenty":-5.708427,"median":-5.1589,"eighty":-4.822536,"marketCap":26215035},{"date":"2023-09-29","current":-4.66902,"twenty":-5.505043,"median":-5.045475,"eighty":-4.536234,"marketCap":27094543},{"date":"2023-10-06","current":-5.250814,"twenty":-5.262548,"median":-5.040586,"eighty":-4.536234,"marketCap":30470722},{"date":"2023-10-13","current":-6.893527,"twenty":-5.817941,"median":-5.065031,"eighty":-4.595684,"marketCap":40003462},{"date":"2023-10-20","current":-8.995809,"twenty":-6.690143,"median":-5.197035,"eighty":-4.691783,"marketCap":52203100},{"date":"2023-10-27","current":-9.201148,"twenty":-7.153624,"median":-5.22148,"eighty":-4.714546,"marketCap":53394692},{"date":"2023-11-03","current":-8.379791,"twenty":-8.309389,"median":-5.27037,"eighty":-4.77036,"marketCap":48628322},{"date":"2023-11-10","current":-9.709606,"twenty":-8.530373,"median":-5.764162,"eighty":-4.78929,"marketCap":56345302},{"date":"2023-11-17","current":-41.851906,"twenty":-9.287195,"median":-5.866832,"eighty":-4.791246,"marketCap":55950767},{"date":"2023-11-24","current":-43.761983,"twenty":-9.977525,"median":-6.385068,"eighty":-4.83818,"marketCap":58504301},{"date":"2023-12-01","current":-41.597229,"twenty":-22.855354,"median":-7.177091,"eighty":-4.969206,"marketCap":55610296},{"date":"2023-12-08","current":-37.39506,"twenty":-39.737313,"median":-7.68555,"eighty":-5.041564,"marketCap":49992521},{"date":"2023-12-15","current":-37.352614,"twenty":-39.16082,"median":-8.389569,"eighty":-5.054275,"marketCap":49935776},{"date":"2023-12-22","current":-28.736045,"twenty":-38.685423,"median":-8.477572,"eighty":-5.063075,"marketCap":38416500},{"date":"2023-12-29","current":-26.825968,"twenty":-38.401034,"median":-8.868694,"eighty":-5.079111,"marketCap":35862966},{"date":"2024-01-05","current":-39.899383,"twenty":-38.549596,"median":-9.044699,"eighty":-5.121353,"marketCap":53340488},{"date":"2024-01-12","current":-39.88198,"twenty":-39.488419,"median":-9.670494,"eighty":-5.172981,"marketCap":53317222},{"date":"2024-01-19","current":-38.625999,"twenty":-39.313626,"median":-10.04206,"eighty":-5.199968,"marketCap":51638132},{"date":"2024-01-26","current":-38.965567,"twenty":-39.313626,"median":-10.775414,"eighty":-5.223436,"marketCap":52092093},{"date":"2024-02-02","current":-34.593614,"twenty":-39.237223,"median":-27.727949,"eighty":-5.242992,"marketCap":46247338},{"date":"2024-02-09","current":-43.719537,"twenty":-39.237223,"median":-28.736045,"eighty":-5.262548,"marketCap":58447556},{"date":"2024-02-16","current":-68.677874,"twenty":-39.888941,"median":-31.961952,"eighty":-5.505043,"marketCap":91813733},{"date":"2024-02-23","current":-59.169936,"twenty":-40.466999,"median":-34.275268,"eighty":-5.692782,"marketCap":79102808},{"date":"2024-03-01","current":-63.372175,"twenty":-41.597229,"median":-35.401364,"eighty":-5.759273,"marketCap":84720676},{"date":"2024-03-08","current":-73.849585,"twenty":-41.945287,"median":-36.142899,"eighty":-5.808163,"marketCap":98727664},{"date":"2024-03-15","current":-76.245081,"twenty":-43.210183,"median":-36.501144,"eighty":-5.849231,"marketCap":101930142},{"date":"2024-03-22","current":-103.758666,"twenty":-50.901256,"median":-37.320992,"eighty":-6.027192,"marketCap":138712367},{"date":"2024-03-28","current":-90.558053,"twenty":-57.709789,"median":-37.373837,"eighty":-6.291199,"marketCap":121064797},{"date":"2024-04-05","current":-61.481111,"twenty":-59.566286,"median":-37.479952,"eighty":-6.48676,"marketCap":133529165},{"date":"2024-04-12","current":-71.595379,"twenty":-59.997513,"median":-38.212361,"eighty":-6.942417,"marketCap":155496070},{"date":"2024-04-19","current":-71.737433,"twenty":-62.930842,"median":-38.413768,"eighty":-7.153624,"marketCap":155804594},{"date":"2024-04-26","current":-94.969175,"twenty":-65.856384,"median":-38.647222,"eighty":-7.237715,"marketCap":206260987},{"date":"2024-05-03","current":-91.738931,"twenty":-67.584491,"median":-38.965567,"eighty":-7.396119,"marketCap":199245307},{"date":"2024-05-10","current":-90.826862,"twenty":-70.379394,"median":-39.220244,"eighty":-7.806798,"marketCap":197264409},{"date":"2024-05-17","current":-48.426621,"twenty":-71.185147,"median":-39.390029,"eighty":-8.309389,"marketCap":201061130},{"date":"2024-05-24","current":-37.632017,"twenty":-70.941929,"median":-39.252477,"eighty":-8.383702,"marketCap":156243317},{"date":"2024-05-31","current":-37.651896,"twenty":-70.600999,"median":-39.231253,"eighty":-8.399347,"marketCap":156325854},{"date":"2024-06-07","current":-38.148885,"twenty":-69.492975,"median":-39.142864,"eighty":-8.458016,"marketCap":158389289},{"date":"2024-06-14","current":-37.791053,"twenty":-68.677874,"median":-39.132924,"eighty":-8.477572,"marketCap":156903616},{"date":"2024-06-21","current":-39.600094,"twenty":-68.284435,"median":-39.132924,"eighty":-8.688778,"marketCap":164414520},{"date":"2024-06-28","current":-34.033815,"twenty":-67.93606,"median":-39.122984,"eighty":-8.944963,"marketCap":141304045},{"date":"2024-07-05","current":-30.813326,"twenty":-67.00636,"median":-39.083225,"eighty":-9.025143,"marketCap":127932985},{"date":"2024-07-12","current":-31.707906,"twenty":-66.374913,"median":-38.90211,"eighty":-9.138568,"marketCap":131647168},{"date":"2024-07-19","current":-32.304293,"twenty":-66.254136,"median":-38.668445,"eighty":-9.459288,"marketCap":134123291},{"date":"2024-07-26","current":-27.89103,"twenty":-66.009803,"median":-38.625997,"eighty":-9.678316,"marketCap":115799986},{"date":"2024-08-02","current":-21.131978,"twenty":-65.799563,"median":-38.413768,"eighty":-9.715473,"marketCap":87737266},{"date":"2024-08-09","current":-18.460659,"twenty":-64.992694,"median":-38.255401,"eighty":-10.106595,"marketCap":93102198},{"date":"2024-08-16","current":-29.88401,"twenty":-63.82037,"median":-38.148885,"eighty":-10.558342,"marketCap":150713310},{"date":"2024-08-23","current":-26.709039,"twenty":-63.123956,"median":-37.878225,"eighty":-10.740213,"marketCap":134701053},{"date":"2024-08-30","current":-30.47318,"twenty":-62.875574,"median":-37.791053,"eighty":-10.88395,"marketCap":153684657},{"date":"2024-09-06","current":-23.484969,"twenty":-62.310952,"median":-37.632017,"eighty":-13.958048,"marketCap":118441183},{"date":"2024-09-13","current":-28.656572,"twenty":-61.520597,"median":-37.39506,"eighty":-19.017097,"marketCap":144523004},{"date":"2024-09-20","current":-27.560062,"twenty":-60.889782,"median":-37.352614,"eighty":-20.363844,"marketCap":138992998},{"date":"2024-09-27","current":-24.761504,"twenty":-59.992238,"median":-37.044217,"eighty":-21.696558,"marketCap":124879101},{"date":"2024-10-04","current":-23.484969,"twenty":-59.885067,"median":-36.618159,"eighty":-21.737099,"marketCap":118441183},{"date":"2024-10-11","current":-22.093874,"twenty":-59.702244,"median":-36.256014,"eighty":-21.195966,"marketCap":111425503},{"date":"2024-10-18","current":-23.40314,"twenty":-59.499033,"median":-36.121676,"eighty":-21.422875,"marketCap":118028496},{"date":"2024-10-25","current":-22.42119,"twenty":-59.246339,"median":-35.506843,"eighty":-21.041389,"marketCap":113076251},{"date":"2024-11-01","current":-20.964631,"twenty":-58.949205,"median":-34.593614,"eighty":-21.041389,"marketCap":105730422},{"date":"2024-11-08","current":-20.522754,"twenty":-58.467774,"median":-33.995368,"eighty":-20.604583,"marketCap":103501912},{"date":"2024-11-15","current":-7.440484,"twenty":-58.205855,"median":-32.960319,"eighty":-20.319817,"marketCap":88892790},{"date":"2024-11-22","current":-6.632186,"twenty":-57.268349,"median":-31.876883,"eighty":-19.75356,"marketCap":79235913},{"date":"2024-11-29","current":-7.461209,"twenty":-55.646905,"median":-31.638328,"eighty":-10.811593,"marketCap":89140402},{"date":"2024-12-06","current":-8.228056,"twenty":-54.314096,"median":-31.509111,"eighty":-9.711562,"marketCap":98302055},{"date":"2024-12-13","current":-1.31262,"twenty":-52.81792,"median":-30.753634,"eighty":-9.005587,"marketCap":15682107},{"date":"2024-12-20","current":-1.540602,"twenty":-48.999152,"median":-30.455494,"eighty":-8.411081,"marketCap":18405842},{"date":"2024-12-27","current":-1.658046,"twenty":-48.426621,"median":-29.978384,"eighty":-8.228056,"marketCap":19808978},{"date":"2025-01-03","current":-1.609687,"twenty":-47.997222,"median":-29.785815,"eighty":-7.657262,"marketCap":19231216},{"date":"2025-01-10","current":-1.457699,"twenty":-47.144687,"median":-29.245398,"eighty":-7.393795,"marketCap":17415393},{"date":"2025-01-17","current":-1.457699,"twenty":-44.916349,"median":-28.653863,"eighty":-7.183487,"marketCap":17415393},{"date":"2025-01-24","current":-1.59587,"twenty":-43.761983,"median":-28.638191,"eighty":-7.010773,"marketCap":19066141},{"date":"2025-01-31","current":-1.561327,"twenty":-43.745005,"median":-28.566935,"eighty":-6.6764,"marketCap":18653454},{"date":"2025-02-07","current":-1.526784,"twenty":-43.24863,"median":-27.889204,"eighty":-6.348881,"marketCap":18240767},{"date":"2025-02-14","current":-1.609687,"twenty":-42.503822,"median":-27.789183,"eighty":-5.849231,"marketCap":19231216},{"date":"2025-02-21","current":-1.575144,"twenty":-42.386727,"median":-27.612716,"eighty":-5.677137,"marketCap":18818529},{"date":"2025-02-28","current":-1.54751,"twenty":-42.123561,"median":-27.159099,"eighty":-5.235169,"marketCap":18488379},{"date":"2025-03-07","current":-1.526784,"twenty":-42.013202,"median":-26.709039,"eighty":-5.079111,"marketCap":18240767},{"date":"2025-03-14","current":-4.449091,"twenty":-41.962266,"median":-26.52242,"eighty":-4.902715,"marketCap":53154092},{"date":"2025-03-21","current":-7.633919,"twenty":-41.885863,"median":-26.463551,"eighty":-4.893488,"marketCap":124361854},{"date":"2025-03-28","current":-5.06435,"twenty":-41.817949,"median":-26.005308,"eighty":-4.799924,"marketCap":82501776},{"date":"2025-04-04","current":-5.919092,"twenty":-41.665143,"median":-25.710723,"eighty":-4.841604,"marketCap":96426126},{"date":"2025-04-11","current":-4.538149,"twenty":-41.597229,"median":-25.473418,"eighty":-4.783424,"marketCap":73929597},{"date":"2025-04-17","current":-5.235298,"twenty":-41.597229,"median":-25.219748,"eighty":-4.791246,"marketCap":85286646},{"date":"2025-04-25","current":-4.61561,"twenty":-41.512337,"median":-24.761504,"eighty":-4.727795,"marketCap":75191492},{"date":"2025-05-02","current":-5.475694,"twenty":-41.298141,"median":-24.40964,"eighty":-4.781468,"marketCap":89202869},{"date":"2025-05-09","current":-4.535478,"twenty":-40.703923,"median":-23.894115,"eighty":-4.754506,"marketCap":73886084},{"date":"2025-05-16","current":-4.092569,"twenty":-40.111614,"median":-23.509518,"eighty":-4.701084,"marketCap":76409872},{"date":"2025-05-23","current":-3.924764,"twenty":-39.899383,"median":-23.40314,"eighty":-4.546794,"marketCap":73276893},{"date":"2025-05-30","current":-3.631106,"twenty":-39.899383,"median":-22.993995,"eighty":-4.534221,"marketCap":67794181},{"date":"2025-06-06","current":-3.514575,"twenty":-39.885461,"median":-22.735979,"eighty":-4.503786,"marketCap":65618501},{"date":"2025-06-13","current":-3.551865,"twenty":-39.7837,"median":-22.503019,"eighty":-4.258784,"marketCap":66314718},{"date":"2025-06-20","current":-3.258207,"twenty":-39.75913,"median":-22.404825,"eighty":-4.158521,"marketCap":60832005},{"date":"2025-06-27","current":-3.311811,"twenty":-39.663708,"median":-22.077508,"eighty":-4.077653,"marketCap":61832818},{"date":"2025-07-03","current":-2.633601,"twenty":-39.550025,"median":-21.823837,"eighty":-3.980044,"marketCap":49170362},{"date":"2025-07-11","current":-3.360754,"twenty":-39.440965,"median":-21.455606,"eighty":-3.896797,"marketCap":62746603},{"date":"2025-07-18","current":-3.528559,"twenty":-39.386585,"median":-21.072854,"eighty":-3.646022,"marketCap":65879582},{"date":"2025-07-25","current":-3.752298,"twenty":-39.349611,"median":-20.964631,"eighty":-3.646022,"marketCap":70056887},{"date":"2025-08-01","current":-3.845523,"twenty":-39.3019,"median":-20.547303,"eighty":-3.685176,"marketCap":71797431},{"date":"2025-08-08","current":-4.353598,"twenty":-39.293948,"median":-20.408193,"eighty":-3.727127,"marketCap":81283395},{"date":"2025-08-15","current":-4.169718,"twenty":-39.274289,"median":-19.933584,"eighty":-3.76778,"marketCap":94285206},{"date":"2025-08-22","current":-3.772796,"twenty":-39.254519,"median":-19.688096,"eighty":-3.760497,"marketCap":85310069},{"date":"2025-08-29","current":-3.813716,"twenty":-39.233455,"median":-10.865861,"eighty":-3.760497,"marketCap":86235341},{"date":"2025-09-05","current":-4.177901,"twenty":-39.220244,"median":-10.526074,"eighty":-3.773614,"marketCap":94470260},{"date":"2025-09-12","current":-3.764612,"twenty":-39.204768,"median":-9.709606,"eighty":-3.773614,"marketCap":85125014},{"date":"2025-09-19","current":-3.314496,"twenty":-39.138888,"median":-9.122923,"eighty":-3.737606,"marketCap":74947023},{"date":"2025-09-26","current":-3.199921,"twenty":-39.116968,"median":-8.741579,"eighty":-3.623336,"marketCap":72356262},{"date":"2025-10-03","current":-3.34314,"twenty":-39.09097,"median":-8.428681,"eighty":-3.551865,"marketCap":75594714},{"date":"2025-10-10","current":-3.494542,"twenty":-39.075273,"median":-8.291789,"eighty":-3.534152,"marketCap":79018220},{"date":"2025-10-17","current":-3.109897,"twenty":-39.027886,"median":-7.962078,"eighty":-3.498549,"marketCap":70320664},{"date":"2025-10-24","current":-2.897115,"twenty":-38.940184,"median":-7.633919,"eighty":-3.482878,"marketCap":65509250},{"date":"2025-10-31","current":-2.909391,"twenty":-38.804612,"median":-7.450846,"eighty":-3.374238,"marketCap":65786832},{"date":"2025-11-07","current":-2.983046,"twenty":-38.663931,"median":-7.254628,"eighty":-3.361323,"marketCap":67452321},{"date":"2025-11-14","current":-2.621936,"twenty":-38.6419,"median":-7.20399,"eighty":-3.333221,"marketCap":67082212},{"date":"2025-11-17","current":-2.777444,"twenty":-38.637925,"median":-7.191777,"eighty":-3.324397,"marketCap":71060881}],"updateTime":1763491252877},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CRVO\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2584962923","title":"Director and 10% Owner Sylvie Gregoire Acquires Common Shares of Cervomed Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2584962923","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584962923?lang=en_us&edition=fundamental","pubTime":"2025-11-17 22:02","pubTimestamp":1763388169,"startTime":"0","endTime":"0","summary":"Sylvie Gregoire, a Director and 10% Owner of CervoMed Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL75WG4s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2584629471","title":"CervoMed CEO John J. Alam Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2584629471","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2584629471?lang=en_us&edition=fundamental","pubTime":"2025-11-17 22:02","pubTimestamp":1763388127,"startTime":"0","endTime":"0","summary":"John J. Alam, CEO and President of Cervomed Inc., reported the acquisition of common shares of Cervomed Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 17, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251117:nNDL35bp8Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CervoMed CEO John J. Alam Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2583542059","title":"CervoMed Executives Make Bold Moves with Significant Stock Purchases!","url":"https://stock-news.laohu8.com/highlight/detail?id=2583542059","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583542059?lang=en_us&edition=fundamental","pubTime":"2025-11-14 10:11","pubTimestamp":1763086310,"startTime":"0","endTime":"0","summary":"New insider activity at CervoMed ( ($CRVO) ) has taken place on November 13, 2025. In a notable series of transactions, key executives at CervoMed ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/insider-trading/cervomed-executives-make-bold-moves-with-significant-stock-purchases-insider-trading?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/insider-trading/cervomed-executives-make-bold-moves-with-significant-stock-purchases-insider-trading?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2583593095","title":"CervoMed CFO William Robert Elder Reports Acquisition of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2583593095","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583593095?lang=en_us&edition=fundamental","pubTime":"2025-11-13 21:52","pubTimestamp":1763041963,"startTime":"0","endTime":"0","summary":"William Robert Elder, CFO, GC & Secretary of Cervomed Inc., reported the acquisition of common shares of Cervomed Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on November 13, 2025, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251113:nNDL7g3wgh:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"CervoMed CFO William Robert Elder Reports Acquisition of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2582908863","title":"CervoMed’s Strategic Advancements and Clinical Trial Developments Drive Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2582908863","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582908863?lang=en_us&edition=fundamental","pubTime":"2025-11-12 05:16","pubTimestamp":1762895763,"startTime":"0","endTime":"0","summary":"In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on CervoMed, with a price target of $20.00. Soumit Roy has given h...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-advancements-and-clinical-trial-developments-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-advancements-and-clinical-trial-developments-drive-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2582366766","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582366766","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582366766?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:33","pubTimestamp":1762864380,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 11, 2025 07:33 ET (12:33 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2582236659","title":"Canaccord Genuity Sticks to Their Buy Rating for CervoMed (CRVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2582236659","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582236659?lang=en_us&edition=fundamental","pubTime":"2025-11-11 20:19","pubTimestamp":1762863554,"startTime":"0","endTime":"0","summary":"In a report released today, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on CervoMed, with a price target of $27.00. Kulkarni cov...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-cervomed-crvo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/canaccord-genuity-sticks-to-their-buy-rating-for-cervomed-crvo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2582804707","title":"CervoMed price target lowered to $19 from $20 at Roth Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2582804707","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582804707?lang=en_us&edition=fundamental","pubTime":"2025-11-11 03:35","pubTimestamp":1762803322,"startTime":"0","endTime":"0","summary":"Roth Capital analyst Boobalan Pachaiyappan lowered the firm’s price target on CervoMed (CRVO) to $19 from $20 and keeps a Buy rating on the shares....","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-lowered-to-19-from-20-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-price-target-lowered-to-19-from-20-at-roth-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2582751998","title":"CervoMed Q3 EPS $(0.84) Misses $(0.49) Estimate, Sales $322.569K Miss $1.300M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2582751998","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582751998?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:21","pubTimestamp":1762777270,"startTime":"0","endTime":"0","summary":"CervoMed (NASDAQ:CRVO) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.49) by 72.13 percent. This is a 52.73 percent decrease over losses of $(0.55) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/11/48748494/cervomed-q3-eps-0-84-misses-0-49-estimate-sales-322-569k-miss-1-300m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0},{"id":"2582587308","title":"CervoMed Q3 net loss widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2582587308","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582587308?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:09","pubTimestamp":1762776576,"startTime":"0","endTime":"0","summary":"CervoMed Q3 net loss widensOverviewCervoMed Q3 2025 net loss of $7.7 mln misses analyst expectationsCash position decreased to $27.3 mln as of September 30, 2025OutlookCervoMed plans to initiate a glo","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nL1N3WM0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2582587373","title":"CervoMed reports Q3 2025 grant revenue of $0.3 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2582587373","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582587373?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:06","pubTimestamp":1762776360,"startTime":"0","endTime":"0","summary":"CervoMed Inc. reported a cash position of $27.3 million as of September 30, 2025, down from $38.9 million at December 31, 2024. The company stated that its current cash, cash equivalents, and marketable securities are expected to fund operations into the third quarter of 2026. Grant revenue for the third quarter of 2025 was $0.3 million, compared to $1.9 million in the same period of 2024, reflecting the completion of the initial and extension phases of the RewinD-LB trial. During the quarter, CervoMed announced new Phase 2b RewinD-LB trial data and the appointment of Matthew Winton as Chief Commercial and Business Officer, as well as David Quigley to the Board of Directors. Initial biomarker data from a Phase 2a trial in frontotemporal dementia and topline results from a Phase 2a trial in stroke recovery are expected in 2026.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251110:nNDL8bHgRq:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2582732158","title":"Press Release: CervoMed Reports Third Quarter 2025 Financial Results and Provides Corporate Updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2582732158","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582732158?lang=en_us&edition=fundamental","pubTime":"2025-11-10 20:00","pubTimestamp":1762776000,"startTime":"0","endTime":"0","summary":"Aligned with U.S Food and Drug Administration  on design of planned Phase 3 clinical trial of neflamapimod in patients with dementia with Lewy bodies . Reported 32-week data from Phase 2b RewinD-LB trial showing neflamapimod treatment in patients with DLB had a durable beneficial effect on clinical progression and resulted in substantial reductions in plasma levels of a well-established biomarker of neurodegeneration. Meeting with global regulators in coming months and preparing for global pivotal trial initiation in second half of 2026. Initial biomarker data from Phase 2a trial in a sub-type of frontotemporal dementia  and topline results from Phase 2a trial in recovery after stroke expected in 2026","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4132","CRVO","AD","LU0348723411.USD","LU0345774631.USD","BK4097","LU0345774391.USD","DLB","LU0205194284.USD","LU0240877869.USD","LU0240878834.USD","LU0205193047.USD"],"gpt_icon":0},{"id":"2581819788","title":"CervoMed Inc  expected to post a loss of 77 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2581819788","media":"Reuters","labels":["dataReport","preview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581819788?lang=en_us&edition=fundamental","pubTime":"2025-11-07 22:51","pubTimestamp":1762527079,"startTime":"0","endTime":"0","summary":"CervoMed Inc  expected to post a loss of77cents a share - Earnings Preview CervoMed Inc CRVO.OQ CRVO.O is expected to  show a fall in quarterly revenue when it reports  results on November 10 (estimat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251107:nL8N3WJ20Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,preview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CRVO"],"gpt_icon":0},{"id":"2581706995","title":"CervoMed Shares Rise After HC Wainwright Upgrade","url":"https://stock-news.laohu8.com/highlight/detail?id=2581706995","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581706995?lang=en_us&edition=fundamental","pubTime":"2025-11-06 03:59","pubTimestamp":1762372766,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) shares were up 6% in recent Wednesday trading after HC Wainwright upgraded the stock to buy from neutral and adjusted its price target to $25 from $11.Trading volume stood at over 74,700 shares, versus the daily average of 108,181.Price: 7.44, Change: +0.42, Percent Change: +5.98","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRVO"],"gpt_icon":0},{"id":"2581245778","title":"Roth MKM Keeps Their Buy Rating on CervoMed (CRVO)","url":"https://stock-news.laohu8.com/highlight/detail?id=2581245778","media":"TIPRANKS","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581245778?lang=en_us&edition=fundamental","pubTime":"2025-11-05 21:35","pubTimestamp":1762349714,"startTime":"0","endTime":"0","summary":"In a report released today, Boobalan Pachaiyappan from Roth MKM reiterated a Buy rating on CervoMed, with a price target of $20.00. According to Ti...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/roth-mkm-keeps-their-buy-rating-on-cervomed-crvo-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/roth-mkm-keeps-their-buy-rating-on-cervomed-crvo-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2581724728","title":"HC Wainwright Upgrades CervoMed to Buy From Neutral, Adjusts Price Target to $25 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2581724728","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581724728?lang=en_us&edition=fundamental","pubTime":"2025-11-05 20:29","pubTimestamp":1762345772,"startTime":"0","endTime":"0","summary":"CervoMed (CRVO) has an average rating of Buy and mean price target of $20.57, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks and ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CRVO"],"gpt_icon":0},{"id":"2581725952","title":"CervoMed upgraded to Buy from Neutral at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2581725952","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581725952?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:15","pubTimestamp":1762341332,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Raghuram Selvaraju upgraded CervoMed (CRVO) to Buy from Neutral with a $25 price target after the company received written ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/cervomed-upgraded-to-buy-from-neutral-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/cervomed-upgraded-to-buy-from-neutral-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO"],"gpt_icon":0},{"id":"2581230577","title":"CervoMed Inc : H.c. Wainwright Raises Target Price to $25 From $11","url":"https://stock-news.laohu8.com/highlight/detail?id=2581230577","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581230577?lang=en_us&edition=fundamental","pubTime":"2025-11-05 19:12","pubTimestamp":1762341156,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251105:nAZN4QKGTL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CRVO","BK4139"],"gpt_icon":0},{"id":"2581757304","title":"CervoMed’s Strategic Phase 3 Trial Progress for Neflamapimod Boosts Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2581757304","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581757304?lang=en_us&edition=fundamental","pubTime":"2025-11-05 01:55","pubTimestamp":1762278911,"startTime":"0","endTime":"0","summary":"Soumit Roy, an analyst from JonesTrading, maintained the Buy rating on CervoMed. The associated price target remains the same with $20.00. Soumit R...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-phase-3-trial-progress-for-neflamapimod-boosts-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/cervomeds-strategic-phase-3-trial-progress-for-neflamapimod-boosts-buy-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CRVO","PRGS"],"gpt_icon":0},{"id":"2580737671","title":"CervoMed Is Maintained at Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2580737671","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2580737671?lang=en_us&edition=fundamental","pubTime":"2025-11-04 21:52","pubTimestamp":1762264320,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/CRVO/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 04, 2025 08:52 ET (13:52 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRVO"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":65,"code":"91000000","status":"200"}]}}